Aspect Biosystems Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Aspect Biosystems's estimated annual revenue is currently $7.6M per year.
- Aspect Biosystems received $2.7M in venture funding in November 2018.
- Aspect Biosystems's estimated revenue per employee is $155,000
- Aspect Biosystems's total funding is $3.7M.
- Aspect Biosystems has 49 Employees.
- Aspect Biosystems grew their employee count by 32% last year.
- Aspect Biosystems currently has 5 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Aspect Biosystems?
Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company's proprietary Lab-on-a-Printer platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.keywords:N/A
Number of Employees
Employee Growth %
Aspect Biosystems News
... Cyfuse Biomedical K.K., BioBots, Aspect Biosystems Ltd., 3Dynamic Systems Ltd., regenHU Ltd, Cellink, Regenovo Biotechnology Co., Ltd., ...
... Inc., 3Dynamics Systems Ltd., Cyfuse Biomedical K.K., LLC Aspect Biosystems Ltd., TeVidoBioDevices, and Stratasys Ltd Competitive Insights & Forecasting ...
... Luxexcel Group BV, Organovo Holding Inc., 3Dynamics Systems, Bio3D Technologies, Envision TEC, Aspect Biosystems, Cyfuse Biomedical ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
Aspect Biosystems Funding
|2018-05-08||$1.0M||Undisclosed||Genome British Columbia||Article|
|2018-11-16||$2.7M||Undisclosed||Western Innovation (WINN) Initiative.||Article|